Edgestream Partners, L.P. Arrowhead Pharmaceuticals, Inc. Transaction History
Edgestream Partners, L.P.
- $2.29 Billion
- Q4 2024
A detailed history of Edgestream Partners, L.P. transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Edgestream Partners, L.P. holds 120,411 shares of ARWR stock, worth $1.78 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
120,411Holding current value
$1.78 Million% of portfolio
0.1%Shares
4 transactions
Others Institutions Holding ARWR
# of Institutions
304Shares Held
95.9MCall Options Held
523KPut Options Held
493K-
Black Rock Inc. New York, NY15.7MShares$232 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$180 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$164 Million3.04% of portfolio
-
State Street Corp Boston, MA6.02MShares$89 Million0.0% of portfolio
-
Slate Path Capital LP New York, NY5.23MShares$77.4 Million1.89% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $1.57B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...